15 April 2020

Moderna has begun enrolment of participants for the highest dose arm of the Phase I clinical trial assessing its mRNA-1273 vaccine candidate against Covid-19. Led by the US National Institutes of Health (NIH), the trial is designed to include arms for 25μg, 100μg and 250μg dose levels of mRNA-1273.

Merck Group subsidiary MilliporeSigma has agreed to support The Jenner Institute in Oxford, UK, in the large-scale manufacturing of the latter’s Covid-19 vaccine candidate, ChAdOx1 nCoV-19. The partners worked together to cut the manufacturing process time from approximately 6-12 months to two months.

NantKwest and ImmunityBio are in discussions with the US Food and Drug Administration (FDA) regarding the development of Covid-19 vaccines and therapeutics. The collaboration combines ImmunityBio’s vaccine development and natural killer cell activation capabilities with NantKwest’s off-the-shelf, cell-based therapeutics expertise. Read the full story here

Clara Health has partnered with Lyft and public relations firm VSC to launch an initiative to enhance Covid-19 participation by matching patients to relevant clinical trials. Clara Health developed a registry platform and database called World Without COVID, which lists more than 300 Covid-19 trials; the database is open for researchers and public.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.